PMID: 6538658May 1, 1984Paper

Frequent neurologic toxicity associated with amiodarone therapy

Neurology
M E CharnessM M Scheinman

Abstract

Fifty-four consecutive patients were treated with amiodarone for symptomatic ventricular tachycardia or ventricular fibrillation refractory to treatment with conventional antiarrhythmic drugs. A reversible neurologic syndrome of tremor, ataxia, and occasionally peripheral neuropathy without nystagmus, dizziness, encephalopathy, or long-tract signs developed in 54% of the patients and was the most common reason for altering or discontinuing drug therapy. Neurologic side effects improved or resolved within 2 days to 4 weeks of decreasing or discontinuing amiodarone. Frequent neurologic toxicity is a hitherto undescribed complication of amiodarone therapy. Wider recognition of this syndrome will avoid unnecessary and costly diagnostic evaluation.

Citations

Jan 1, 1991·European Journal of Clinical Pharmacology·A A LakhdarF G Dunn
Dec 1, 1987·Italian Journal of Neurological Sciences·F CarellaA Mangoni
Mar 1, 1987·Current Problems in Cardiology·A C Cuetter, V J Ferrans
Oct 28, 1999·Clinical Neurology and Neurosurgery·G Sclar
Sep 5, 2001·Neurologic Clinics·T A Zesiewicz, R A Hauser
Mar 1, 1996·Journal of Clinical Neurophysiology : Official Publication of the American Electroencephalographic Society·R J Elble
Mar 1, 2002·Journal of Clinical Neuromuscular Disease·Uma PulipakaBennet Omalu
Jul 1, 1994·Postgraduate Medical Journal·R ShuklaJ E Pohl
Mar 1, 1988·The American Review of Respiratory Disease·M J ReasorS Kacew
Nov 14, 2014·CNS Drugs·J van GaalenB P C van de Warrenburg
Oct 7, 2008·Psychiatry·Monica R SantosDouglas F Zatzick
Feb 14, 2012·Expert Opinion on Drug Safety·Pasquale SantangeliAndrea Natale
May 20, 2015·Expert Opinion on Drug Safety·Dénes ZádoriLászló Vécsei
Feb 26, 2016·Current Neurology and Neuroscience Reports·Elliot T Dawson, Sara E Hocker
Aug 1, 1987·Mayo Clinic Proceedings·L A FeinerF T Fraunfelder
May 5, 2010·The American Journal of Geriatric Pharmacotherapy·Kevin T Foley, Karen S Bugg
May 9, 2009·The Journal of Foot and Ankle Surgery : Official Publication of the American College of Foot and Ankle Surgeons·Ketan DhatariyaRachael Hutchinson
Feb 28, 2007·Neurologic Clinics·Zachary London, James W Albers
May 3, 2014·Basic & Clinical Pharmacology & Toxicology·Ole Jakob VilholmMustapha Itani
Mar 27, 2016·Archives of Toxicology·Marilena ColaiannaKarl-Heinz Krause
May 1, 1989·Progress in Cardiovascular Diseases·T R VrobelL Rakita
Oct 1, 1989·Australian and New Zealand Journal of Medicine·P D Clouston, P E Donnelly
Jun 1, 1989·Annals of Neurology·E G Werner, C W Olanow
Jun 1, 1985·Australian and New Zealand Journal of Medicine·N E AndersonK P O'Brien
May 1, 1989·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·J H LewisH J Zimmerman
Nov 9, 2005·The American Journal of Cardiology·Daniel G KrauserPaul Kligfield
Jan 23, 1999·Archives of Physical Medicine and Rehabilitation·P H Katrak
Mar 6, 2012·The American Journal of Medicine·Rod S PassmanJune M McKoy
Jun 1, 1986·The American Journal of Cardiology·W M SmithA H Roche
Aug 1, 1988·The American Journal of Medicine·W J PichlerA L de Weck
Aug 10, 2015·European Journal of Drug Metabolism and Pharmacokinetics·Jing-Tao LuYuan-Sheng Zhao
Dec 15, 2007·Thérapie·Issam SalouageChalbi Belkahia
Feb 19, 1987·The New England Journal of Medicine·J W Mason
May 1, 1992·La Revue de médecine interne·C MassonD Hénin
Jun 29, 2000·Neurologic Clinics·M B Bromberg
Feb 25, 1998·Pacing and Clinical Electrophysiology : PACE·M Jafari-Fesharaki, M M Scheinman
Mar 6, 2018·Neurology India·Nitish Kamble, Pramod Kumar Pal
Mar 7, 2009·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Mina S Willis, Amy M Lugo
Dec 1, 1994·Arquivos de neuro-psiquiatria·N S GarrettoR E Sica
Mar 22, 2018·Frontiers in Neurology·Robert Gürkov
Mar 30, 2017·Neuro-ophthalmology·An-Guor Wang, Hui-Chen Cheng
Nov 23, 2019·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Nebojša MujovićTatjana S Potpara
Mar 24, 2021·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·Francesco BaxGian Luigi Gigli

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.

Ataxias

Ataxia is a neurological condition characterized by lack of voluntary coordination of muscle movements including loss of coordination, balance, and speech. Discover the latest research on different types of ataxias here.

Ataxias (MDS)

Ataxia is a neurological condition characterized by lack of voluntary coordination of muscle movements including loss of coordination, balance, and speech. Discover the latest research on ataxia here.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Ataxia

Ataxia is a neurological condition characterized by lack of voluntary coordination of muscle movements including loss of coordination, balance, and speech. Discover the latest research on ataxia here.

Related Papers

Neurology
A Martinez-ArizalaL Rakita
Australian and New Zealand Journal of Medicine
N E AndersonK P O'Brien
Journal of Neurology, Neurosurgery, and Psychiatry
A G FraserM R Stephens
© 2021 Meta ULC. All rights reserved